<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732743</url>
  </required_header>
  <id_info>
    <org_study_id>IU01/016</org_study_id>
    <nct_id>NCT02732743</nct_id>
  </id_info>
  <brief_title>Food Supplement Physiomanna® Baby in Pediatric Patients</brief_title>
  <official_title>An Open Label, Non-comparative Pilot Study to Assess the Efficacy and Safety of the Food Supplement Physiomanna® Baby in Pediatric Patients With a History of Functional Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iuppa Industriale Srl</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opera Contract Research Organization SRL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iuppa Industriale Srl</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the efficacy and safety of the Food Supplement
      Physiomanna® Baby in pediatric patients with a history of functional constipation

      The secondary objective of the trial is to evaluate the adherence to product's administration
      in the enrolled children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, non-controlled, multicenter trial with a prospective design in one
      cohort of patients. This clinical investigation will be performed in 3 centers in Romania.

      The tested hypothesis is that Physiomanna® Baby administration for 3 weeks, increases the SBM
      to be more than 2 times per week.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Spontaneous Bowel Movements (SBM) per week</measure>
    <time_frame>2-3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Events (AE) check; Investigator and Patient Global Assessment</measure>
    <time_frame>2-3 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Investigator and Patient Global Assessment for Efficacy</measure>
    <time_frame>2-3 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of product's administration adherence by diary cards</measure>
    <time_frame>2-3 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
  <arm_group>
    <arm_group_label>Food Supplement Physiomanna® Baby</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dosage: 1g/kg body</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Physiomanna® Baby</intervention_name>
    <description>Dosage 1g/kg body, 2 cycles (if applicable)</description>
    <arm_group_label>Food Supplement Physiomanna® Baby</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients between the ages of 0 to 8 years;

          -  Functional constipation according to ROME III criteria (Annex 2);

          -  Two or fewer SBM during the previous week; SBM is defined as BM not preceded after a
             24 h administration with a laxative or enema;

          -  To be otherwise in good health, as judged by a physical examination;

          -  Mentally competent parent or tutor to sign an informed consent

        Exclusion Criteria:

          -  Known history of organic cause for the constipation;

          -  Congenital malformations that produce constipation (Hirschsprung's disease,
             imperforate anus, children with cerebral palsy or other neurologic abnormalities, or
             systemic diseases);

          -  Fecal Occult Blood Test (FOBT) positive in the 4 previous weeks;

          -  Fecal impaction at baseline, or during the trial period, as indicated by the physical
             examination;

          -  Known or suspected perforation or obstruction other than fecal impaction;

          -  History of gastric retention, inflammatory bowel disease, bowel resection, or
             colostomy;

          -  Use of concomitant medications that cause constipation in the previous 3 months;

          -  Concomitant use of herbs and other dietary supplements, such as: stimulant laxative
             herbs and/or potassium depleting herbs;

          -  Concomitant use of cardiac glycosides(e.g. Digoxin);

          -  Patients who, according to the investigator, should not be included in the study for
             any reason, including the parent's inability to follow the study procedures;

          -  Patients with known allergy to Fraxinus Manna, mannitole, fennel, lemon balm or
             chamomile;

          -  Patients with clinically significant elevations of TSH or abnormal plasma electrolytes
             in the 4 previous weeks;

          -  Patients who, within the past 30 days have participated in an investigational clinical
             study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barattini Dionisio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Opera CRO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Opera Contract Research Organization SRL</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300209</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Tabbers MM, Boluyt N, Berger MY, Benninga MA. Clinical practice : diagnosis and treatment of functional constipation. Eur J Pediatr. 2011 Aug;170(8):955-63. doi: 10.1007/s00431-011-1515-5. Epub 2011 Jun 24. Review.</citation>
    <PMID>21701812</PMID>
  </reference>
  <reference>
    <citation>Tabbers MM, Boluyt N, Berger MY, Benninga MA. Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics. 2011 Oct;128(4):753-61. doi: 10.1542/peds.2011-0179. Epub 2011 Sep 26. Review.</citation>
    <PMID>21949142</PMID>
  </reference>
  <reference>
    <citation>Loening-Baucke V, Miele E, Staiano A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation. Pediatrics. 2004 Mar;113(3 Pt 1):e259-64.</citation>
    <PMID>14993586</PMID>
  </reference>
  <reference>
    <citation>Livesey G. Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties. Nutr Res Rev. 2003 Dec;16(2):163-91. doi: 10.1079/NRR200371.</citation>
    <PMID>19087388</PMID>
  </reference>
  <reference>
    <citation>Caligiani A, Tonelli L, Palla G, Marseglia A, Rossi D, Bruni R. Looking beyond sugars: phytochemical profiling and standardization of manna exudates from Sicilian Fraxinus excelsior L. Fitoterapia. 2013 Oct;90:65-72. doi: 10.1016/j.fitote.2013.07.002. Epub 2013 Jul 10.</citation>
    <PMID>23850543</PMID>
  </reference>
  <reference>
    <citation>Kountouras J, Magoula I, Tsapas G, Liatsis I. The effect of mannitol and secretin on the biliary transport of urate in humans. Hepatology. 1996 Feb;23(2):229-33.</citation>
    <PMID>8591845</PMID>
  </reference>
  <reference>
    <citation>Taylor SN, Basile LA, Ebeling M, Wagner CL. Intestinal permeability in preterm infants by feeding type: mother's milk versus formula. Breastfeed Med. 2009 Mar;4(1):11-5. doi: 10.1089/bfm.2008.0114.</citation>
    <PMID>19196035</PMID>
  </reference>
  <reference>
    <citation>Ummarino D, Martinelli M, Giugliano FP, Tortora C, Valenti S, Pidone C, De Giovanni D, Rutigliano I, Campanozzi A, Romano C, Miele E, Staiano A. PP-12 EFFICACY OF A STANDARDIZED EXTRACT OF MATRICARIAE CHAMOMILLA L., MELISSA OFFICINALIS L. AND TYNDALLIZED LACTOBACILLUS ACIDOPHILUS (H122) COMPARED WITH LACTOBACILLUS REUTERI (DSM 17938) AND WITH SIMETHICONE FOR THE TREATMENT OF INFANTILE COLIC. J Pediatr Gastroenterol Nutr. 2015 Oct;61(4):525. doi: 10.1097/01.mpg.0000472240.67602.a9.</citation>
    <PMID>26439577</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhod constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

